TOLREMO was founded on pioneering expertise in non-mutational drug resistance to deliver a new wave of resistance-preventing precision therapies to patients with cancer. Their proprietary drug discovery engine enables the identification of novel drug resistance regulators and the development of small molecule therapies against these promising drug targets. TOLREMO’s therapies aim to complement standard cancer therapies to offer better response rates, longer survival and improved quality of life.
Highlights from the 45-patient study:
▪️ 10 of 24 NSCLC patients (42%) showed tumour shrinkage, with confirmed partial responses across three biologically distinct resistance settings
▪️ 60 mg once daily established as the recommended dose
▪️ Differentiated safety profile — 98% of treatment-related adverse events Grade 1 or 2, no thrombocytopenia
TOLREMO co-founder and CEO Dr. Stefanie Flückiger-Mangual has won the POWHER 2026 Emerging Entrepreneur of the Year award.
Stefanie Flückiger-Mangual, founder and CEO of TOLREMO therapeutics, was nominated for the 2026 POWHER Emerging Entrepreneur of the Year award.
The Strüngmann Award 2025 for revolutionary technologies in the life sciences sector in the DACH region will be presented to Araris in Au, NovaGo in Schlieren or Tolremo in Basel. (Article in German)
TOLREMO therapeutics AG (TOLREMO) today announced the appointment of Alan Sandler, M.D., to its Scientific Advisory Board (SAB).
TOLREMO therapeutics has completed its Series A financing, bringing the total amount raised to USD 39 million (CHF 34.1 million). BioMedPartners AG led the round with participation from a new investor, Pierre Fabre Invest, and existing investors…
| Building | C2 |
|---|---|
| Industry | Biotech |
| Employees | 5 |
| Founding year | 2017 |
Home 
About us 
Offer 
News 
Financial support for start-ups in Basel 
Media 
Contact 